Controversies related to renal artery denervation and devices.
Journal
Current opinion in cardiology
ISSN: 1531-7080
Titre abrégé: Curr Opin Cardiol
Pays: United States
ID NLM: 8608087
Informations de publication
Date de publication:
04 Apr 2024
04 Apr 2024
Historique:
medline:
3
4
2024
pubmed:
3
4
2024
entrez:
3
4
2024
Statut:
aheadofprint
Résumé
This review article discusses the controversies, strengths, and limitations of the current literature on renal artery denervation in the management of resistant hypertension, as well as the future directions of this intervention. There have been conflicting data from the different randomized control trials assessing the efficacy of renal artery denervation in the management of resistant hypertension. Renal artery denervation is achieved by ablating the sympathetic nerves surrounding the renal arteries using endovascular ultrasound, radiofrequency, or alcohol. Our review article highlights that renal artery denervation is generally effective in improving blood pressure in patients with resistant hypertension. The Food and Drug Administration (FDA) has recently approved the ReCor Medical Paradise system, and the Symplicity Spyral RDN systems for renal artery denervation.
Identifiants
pubmed: 38567924
doi: 10.1097/HCO.0000000000001146
pii: 00001573-990000000-00148
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 2020; 75:1334–1357.
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71:1269–1324.
Facts about hypertension CdC.gov. (2023, July 6). Centers for Disease Control and Prevention. https://www.cdc.gov/bloodpressure/facts.htm#:∼:text=In%202021%2C%20hypertension%20was%20a,deaths%20in%20the%20United%20States.&text=Nearly%20half%20of%20adults%20have,are%20taking%20medication%20for%20hypertension. 2023.
Kirkland EB, Heincelman M, Bishu KG, et al. Trends in healthcare expenditures among US adults with hypertension: national estimates, 2003–2014. J Am Heart Assoc 2018; 7:e008731.
Jaeger BC, Chen L, Foti K, et al. Hypertension statistics for US adults: an open-source web application for analysis and visualization of National Health and Nutrition Examination Survey Data. Hypertension 2023; 80:1311–1320.
Nazarzadeh M, Pinho-Gomes A-C, Rahimi K. Resistant hypertension in times of changing definitions and treatment recommendations. Heart 2019; 105:96–97.
Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension 2018; 72:e53–e90.
Muntner P, Davis BR, Cushman WC, et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease. Hypertension 2014; 64:1012–1021.
Azizi M, Saxena M, Wang Y, et al. Endovascular ultrasound renal denervation to treat hypertension. JAMA 2023; 329:651–661.
Bhatt DL, Vaduganathan M, Kandzari DE, et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet 2022; 400:1405–1416.
Azizi M, Sanghvi K, Saxena M, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet 2021; 397:2476–2486.
Tsioufis C, Kordalis A, Flessas D, et al. Pathophysiology of resistant hypertension: the role of sympathetic nervous system. Int J Hypertens 2011; 2011:642416.
Townsend RR, Epstein M. Resistant hypertension: insights on evaluation and management in the post-SPRINT (Systolic Blood Pressure Intervention Trial) era. Hypertension 2016; 68:1073–1080.
Schlaich MP, Esler MD, Fink GD, et al. Targeting the sympathetic nervous system. Hypertension 2014; 63:426–432.
Armitage JA, Burke SL, Prior LJ, et al. Rapid onset of renal sympathetic nerve activation in rabbits fed a high-fat diet. Hypertension 2012; 60:163–171.
Muntzel MS, Al-Naimi OA, Barclay A, Ajasin D. Cafeteria diet increases fat mass and chronically elevates lumbar sympathetic nerve activity in rats. Hypertension 2012; 60:1498–1502.
Denker MG, Cohen DL. Resistant hypertension and renal nerve denervation. Methodist Debakey Cardiovasc J 2015; 11:240–244.
Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386:2059–2068.
Tadic M, Cuspidi C. Obesity and resistant hypertension: never ending story. J Clin Hypertens (Greenwich) 2019; 21:1516–1518.
Osborn JW, Tyshynsky R, Vulchanova L. Function of renal nerves in kidney physiology and pathophysiology. Annu Rev Physiol 2021; 83:429–450.
Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 2018; 391:2335–2345.
Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet 2022; 399:1401–1410.
Kario K, Mahfoud F, Kandzari DE, et al. Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial. Hypertens Res 2022; 46:280–288.
Mahfoud F, Renkin J, Sievert H, et al. Alcohol-mediated renal denervation using the Peregrine system infusion catheter for treatment of hypertension. JACC Cardiovasc Interv 2020; 13:471–484.
Fischell TA, Ebner A, Gallo S, et al. Transcatheter alcohol-mediated perivascular renal denervation with the Peregrine system: first-in-human experience. JACC Cardiovasc Interv 2016; 9:589–598.
Liu H, Chen W, Lai Y, et al. Selective renal denervation guided by renal nerve stimulation in canine. Hypertension 2019; 74:536–545.
Bohm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet 2020; 395:1444–1451.
Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370:1393–1401.
Kandzari DE, Bhatt DL, Brar S, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J 2014; 36:219–227.
Pathak A, Rudolph UM, Saxena M, et al. Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications. EuroIntervention 2023; 19:602–611.
Kario K, Yokoi Y, Okamura K, et al. Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. Hypertens Res 2021; 45:221–231.
Sesa-Ashton G, Nolde JM, Muente I, et al. Catheter-based renal denervation: 9-year follow-up data on safety and blood pressure reduction in patients with resistant hypertension. Hypertension 2023; 80:811–819.
Mahfoud F, Böhm M, Schmieder R, et al. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J 2019; 40:3474–3482.
Schmieder R, Burnier M, East C, et al. Renal denervation: a practical guide for health professionals managing hypertension. Interv Cardiol 2023; 18:e06.
Peeters LEJ, Feyz L, Boersma E, et al. Clinical applicability of monitoring antihypertensive drug levels in blood. Hypertension 2020; 76:80–86.
Lane D, Lawson A, Burns A, et al. Nonadherence in hypertension: how to develop and implement chemical adherence testing. Hypertension 2022; 79:12–23.
Cai A, Calhoun DA. Resistant hypertension: an update of experimental and clinical findings. Hypertension 2017; 70:5–9.